Inflammation Research

, Volume 59, Issue 5, pp 399–405 | Cite as

A 12-week regimen of caloric restriction improves levels of adipokines and pro-inflammatory cytokines in Korean women with BMIs greater than 23 kg/m2

Original Research Paper



Adipose tissue mass (ATM) is an important source of adipokines. Increases in ATM contribute to chronic low-grade inflammation characterized by high levels of pro-inflammatory cytokines. We investigated the effects of body fat reduction on blood levels of adipokines and pro-inflammatory cytokines in Korean women with BMIs >23 kg/m2.


A total of 46 healthy women participated in the study. A registered dietician supervised the subjects as they conformed to a program of caloric restriction during a 12-week experimental period. Anthropometric assessments were carried out, and blood levels of lipids, adipokines, and pro-inflammatory cytokines were analyzed at the beginning and the end of the experiment.


Body weight and body fat mass decreased significantly in our subjects after 12 weeks of caloric restriction (p < 0.001). Blood levels of triacylglycerol were significantly reduced in accordance with body fat reduction. However, the other blood lipid parameters were unchanged. Adipokine, leptin, and visfatin levels decreased significantly, while adiponectin increased significantly (p < 0.05). Levels of pro-inflammatory cytokines TNF-α and IFN-γ were significantly reduced (p < 0.05).


Our results indicate that body fat reduction via caloric restriction positively affects the blood levels of adipokines and pro-inflammatory cytokines.


Calorie restriction Fat mass Adipokines Pro-inflammatory cytokines Korean 


  1. 1.
    Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004;291:2847–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, et al. Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res. 2007;41:686–93.CrossRefPubMedGoogle Scholar
  6. 6.
    Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2008;19:329–45.PubMedGoogle Scholar
  7. 7.
    Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093–103.PubMedGoogle Scholar
  9. 9.
    Busso N, So A, Chobaz-Péclat V, Morard C, Martinez-Soria E, Talabot-Ayer D, et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol. 2002;168:875–82.PubMedGoogle Scholar
  10. 10.
    Beltowski J. Adiponectin and resistin—new hormones of white adipose tissue. Med Sci Monit. 2003;9:RA55–61.Google Scholar
  11. 11.
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol. 2006;5:10.CrossRefPubMedGoogle Scholar
  13. 13.
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cyclo AMP and tumor necrosis factor alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Hormone Metab Res. 2000;32:548–54.CrossRefGoogle Scholar
  16. 16.
    Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, et al. Adiponectin specifically increased tissue inhibitor of metalloprotenase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005;64:163–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004;30:13–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.CrossRefPubMedGoogle Scholar
  22. 22.
    de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antmann EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and longterm clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Fernandes G. Progress in nutritional immunology. Immunol Res. 2008;40:244–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Wang J, Laferrère B, Thornton JC, Pierson RN Jr, Pi-Sunyer FX. Regional subcutaneous-fat loss induced by caloric restriction in obese women. Obes Res. 2002;10:885–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Martin CK, Heilbronn LK, de Jonge L, DeLany JP, Volaufova J, Anton SD, Redman LM, Smith SR, Ravussin E. Effect of calorie restriction on resting metabolic rate and spontaneous physical activity. Obesity 2007;15:2964–73.Google Scholar
  26. 26.
    Christou NV, Sampalis JS, Liberman M, Look D, Auger S, McLean AP, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg. 2004;199:543–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81:1253–4.Google Scholar
  30. 30.
    Farnsworth E, Luscombe ND, Noakes M, Wittert G, Argyiou E, Clifton PM. Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am J Clin Nutr. 2003;781:31–9.Google Scholar
  31. 31.
    Bimenya GS, Okot JK, Nangosa H, Anguma SA, Byarugaba W. Plasma cholesterol and related lipid levels of seemingly healthy public service employees in Kampala, Uganda. Afr Health Sci. 2006;6:139–44.PubMedGoogle Scholar
  32. 32.
    Dvoráková-Lorenzová A, Suchánek P, Havel PJ, Stávek P, Karasová L, Valenta Z, et al. The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism. 2006;55:359–65.CrossRefPubMedGoogle Scholar
  33. 33.
    Morgan K, Obici S, Rossetti L. Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J Biol Chem. 2004;279(30):31139–48.CrossRefPubMedGoogle Scholar
  34. 34.
    Chearskul S, Delbridge E, Shulkes A, Proietto J, Kriketos A. Effect of weight loss and ketosis on postprandial cholecystokinin and free fatty acid concentrations. Am J Clin Nutr. 2008;87:1238–46.PubMedGoogle Scholar
  35. 35.
    Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res. 1996;82:245–55.CrossRefPubMedGoogle Scholar
  36. 36.
    Ford ES. Body mass index, diabetes and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Ryan AS, Berman DM, Nicklas BJ, Sinha M, Gingerich RL, Meneilly GS, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care. 2003;26:2383–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol. 2004;55:137–54.PubMedGoogle Scholar
  39. 39.
    Konturek PC, Brzozowski T, Burnat G, Kwiecien S, Pawlik T, Hahn EG, et al. Role of brain-gut axis in healing of gastric ulcers. J Physiol Pharmacol. 2004;55:179–92.PubMedGoogle Scholar
  40. 40.
    Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–51.PubMedGoogle Scholar
  41. 41.
    Zozulinka D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia. 1999;42:117–8.Google Scholar
  42. 42.
    Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105:804–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res. 2003;11:1048–54.CrossRefPubMedGoogle Scholar
  44. 44.
    Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag, Basel/Switzerland 2009

Authors and Affiliations

  1. 1.Department of Medical Nutrition, Graduate School of East-West Medical ScienceKyung Hee UniversityYonginKorea
  2. 2.Research Institute of Clinical NutritionKyung Hee UniversitySeoulKorea

Personalised recommendations